Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:42:44.952Z.
Calculation as of: 2026-10-06T15:42:44.952Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Market Cap
$567.12M
PE Ratio
N/A
TTM Avg
80.35
3Y Avg
49.81
5Y Avg
49.81
Market Cap
$577.15M
PE Ratio
N/A
TTM Avg
506.15
3Y Avg
506.15
5Y Avg
506.15
Market Cap
$542.13M
PE Ratio
1208.02
TTM Avg
806.49
3Y Avg
715.80
5Y Avg
715.80
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $560.05M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $556.73M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $567.12M | N/A | 80.35 | 49.81 | 49.81 |
| CorMedix Inc. (CRMD)vs › | $567.21M | 3.39 | 5.18 | 15.60 | 15.60 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.32M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $577.15M | N/A | 506.15 | 506.15 | 506.15 |
| Delcath Systems, Inc. (DCTH)vs › | $542.13M | 1208.02 | 806.49 | 715.80 | 715.80 |
| ProKidney Corp. (PROK)vs › | $539.69M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $539.67M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
